Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners Summer 2022 Investor Conference taking place virtually on June 21-22, 2022.

The Company’s webcast presentation will be available for viewing at 9:00 am ET on Tuesday, June 21, 2022, on the Company’s website (https://irdirect.net/AYTU/corporate_document/2009) or at https://wsw.com/webcast/lytham5/aytu/2067180. The webcast will also be archived and available for replay.

Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register at www.lythampartners.com/summer2022invreg/.

About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKCβ inhibitor in development for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received Orphan Drug designation and Fast Track designation from the U.S. Food and Drug Administration and has received Orphan Drug designation from the European Commission. Aytu is also researching and advancing the development of the Healight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential application in the treatment of severe, difficult-to-treat respiratory infections. To learn more, please visit aytubio.com.

CONTACT:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc
moki@aytubio.com

SOURCE: Aytu BioPharma, Inc.

View source version on accesswire.com:
https://www.accesswire.com/704119/Aytu-BioPharma-to-Participate-in-the-Lytham-Partners-Summer-2022-Investor-Conference